Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with... Oncol Ther (2017) 5:119–123 DOI 10.1007/s40487-017-0040-8 CASE SERIES Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer Harri Visapa ¨a ¨ Received: December 14, 2016 / Published online: February 9, 2017 The Author(s) 2017. This article is published with open access at Springerlink.com injections were switched to the 3-monthly ABSTRACT leuprorelin acetate implant (Leuprorelin Sandoz ) subcutaneous injections. Introduction: Luteinizing hormone-releasing Results: Mean patient age was 75 years (SD 8.3; hormone (LHRH) analogues are widely used range 59–85) and Gleason scores ranged from 7 for the treatment of advanced to 9. The mean [±standard deviation (SD)] hormone-dependent prostate cancer. However, duration of degarelix treatment was there are currently no clinical guidelines for 5 ± 3.7 months (range 2–13). After switching, switching between LHRH analogues. It has been prostate serum antigen levels were comparable reported that there may be clinical benefits for or reduced from those measured prior to patients switching between different switching, showing that efficacy was not formulations of LHRH agonists, as well as from compromised. Throughout the course of an LHRH agonist to LHRH antagonist, but there treatment, no patients reported injection site are no published http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer

Visapää, Harri
Oncology and Therapy , Volume 5 (1) – Feb 9, 2017
Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/switching-from-an-lhrh-antagonist-to-an-lhrh-agonist-a-case-report-of-RBiThfvDmo

References (17)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0040-8
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:119–123 DOI 10.1007/s40487-017-0040-8 CASE SERIES Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer Harri Visapa ¨a ¨ Received: December 14, 2016 / Published online: February 9, 2017 The Author(s) 2017. This article is published with open access at Springerlink.com injections were switched to the 3-monthly ABSTRACT leuprorelin acetate implant (Leuprorelin Sandoz ) subcutaneous injections. Introduction: Luteinizing hormone-releasing Results: Mean patient age was 75 years (SD 8.3; hormone (LHRH) analogues are widely used range 59–85) and Gleason scores ranged from 7 for the treatment of advanced to 9. The mean [±standard deviation (SD)] hormone-dependent prostate cancer. However, duration of degarelix treatment was there are currently no clinical guidelines for 5 ± 3.7 months (range 2–13). After switching, switching between LHRH analogues. It has been prostate serum antigen levels were comparable reported that there may be clinical benefits for or reduced from those measured prior to patients switching between different switching, showing that efficacy was not formulations of LHRH agonists, as well as from compromised. Throughout the course of an LHRH agonist to LHRH antagonist, but there treatment, no patients reported injection site are no published

Journal

Oncology and Therapy – Springer Journals

Published: Feb 9, 2017

There are no references for this article.